GlassScriptPhysician profile
Stephen M Reeder
NPI 1356441851
$3,309.06
in general payments reported to CMS, 2019-2025
32 companies · $847 in 2025
The $847 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,276 · 2020: $298 · 2021: $5.75 · 2022: $55.49 · 2023: $250 · 2024: $576 · 2025: $847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $758.72 | 2019-2025 | Freestyle Libre |
| Amgen INC. | $375.14 | 2019-2025 | Evenity, Tepezza, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.43 | 2019-2023 | Jardiance |
| Pfizer INC. | $239.85 | 2019-2024 | |
| Novo Nordisk INC | $233.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $188.75 | 2019 | |
| Globus Medical, INC. | $181.95 | 2025 | Senza |
| Astrazeneca Pharmaceuticals LP | $153.53 | 2019-2020 | |
| Antares Pharma, INC. | $151.18 | 2019-2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $92.89 | 2023-2025 | |
| Recordati_rare_diseases_inc. | $83.05 | 2024 | Isturisa, Signifor Lar |
| Dexcom, INC. | $75.05 | 2019-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $71.07 | 2019 | |
| Lilly USA, LLC | $49.32 | 2019-2022 | |
| Radius Health, INC. | $47.56 | 2023-2025 | Tymlos |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $43.06 | 2025 | |
| Amarin Pharma, INC. | $38.27 | 2019 | |
| Medtronic Minimed, INC. | $30.45 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.42 | 2019-2020 | |
| Shire North American Group INC | $22.78 | 2019 | |
| Alvogen INC | $22.73 | 2024 | Teriparatide |
| Otsuka America Pharmaceutical, INC. | $22.27 | 2024 | Rexulti |
| Ipsen Biopharmaceuticals, INC | $20.32 | 2019 | |
| Averitas Pharma INC. | $19.37 | 2024 | Qutenza |
| Idorsia Pharmaceuticals US INC | $16.82 | 2023 | Quviviq |
| Amryt Pharma Holdings LTD | $15.98 | 2023 | Mycapssa |
| Abbvie INC. | $15.22 | 2020 | |
| Alfasigma USA, INC. | $13.40 | 2020 | |
| Xeris Pharmaceuticals, INC. | $13.18 | 2024 | Recorlev |
| Aegerion Pharmaceuticals, INC. | $12.08 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.08 | 2019 | |
| Clarus Therapeutics INC. | $5.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Reeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.